Consistent with the phenotype discovered for IL-9 deficient mice, intraperitoneal anti-IL-9 antibody treatment in WT mice resulted in increased body weight and an increased tumor rejection (Figures 8B–D) as compared to control IgG-treated WT animals. Here, IL9 is linked to neoplasm.